On July 8, 2025, Rallybio Corp sold 50% of its ENPP1 joint venture to Recursion Pharmaceuticals for $7.5 million in cash and shares. Additionally, they could earn up to $12.5 million more based on certain milestones and will receive royalties on net sales of related products.